KGK Science Secures Growth Investment to Expand Clinical Trial and Regulatory Capacity
- KGK Science, a North American CRO specializing in dietary supplement and nutraceutical trials, received a growth investment led by Maxim Partners, closing June 30, 2026.
- Capital will fund expanded clinical trial capacity, decentralized and virtual trial capabilities, and growth of regulatory services for consumer health clients.
- KGK has completed over 400 clinical trials across 40+ indications since 1997, with founder and CEO Najla Guthrie remaining in leadership.
Operational Impact
KGK's expanded decentralized and virtual trial capacity may increase availability of specialized clinical research infrastructure for dietary supplement and nutraceutical sponsors seeking North American CRO partners.
Source: PR Newswire pharma category RSS
FDA Expedited IND Pilot Program Webinar: QRI Network for First-in-Human Trials
- FDA is proposing an Expedited IND pilot program to accelerate drug identification to first-in-human clinical trial entry.
- The program would establish a network of Qualified Research Institutions (QRIs)—including CROs, academic medical centers, and regulatory advisors—to partner with sponsors on FIH protocol development and review.
- Educational webinar scheduled August 6, 2026; public comment period closes August 24, 2026.
Operational Impact
CROs designated as Qualified Research Institutions under this pilot may gain formal FDA recognition for protocol development and review services, potentially creating new contractual pathways for sponsors seeking expedited IND entry.
Source: FDA What's New Drugs RSS